Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
KERX's Cash to Debt is ranked higher than
95% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. KERX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KERX' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6548
N/A
No Debt
Equity to Asset 0.78
KERX's Equity to Asset is ranked higher than
63% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. KERX: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
KERX' s Equity to Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.83 Max: 0.93
Current: 0.78
-0.06
0.93
Interest Coverage No Debt
KERX's Interest Coverage is ranked higher than
93% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KERX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KERX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -0.83
M-Score: 16.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1479.47
KERX's Operating margin (%) is ranked lower than
81% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. KERX: -1479.47 )
Ranked among companies with meaningful Operating margin (%) only.
KERX' s Operating margin (%) Range Over the Past 10 Years
Min: -15010.67  Med: -2502.89 Max: 38.97
Current: -1479.47
-15010.67
38.97
Net-margin (%) -1484.12
KERX's Net-margin (%) is ranked lower than
81% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. KERX: -1484.12 )
Ranked among companies with meaningful Net-margin (%) only.
KERX' s Net-margin (%) Range Over the Past 10 Years
Min: -13813.48  Med: -2575.93 Max: 41.62
Current: -1484.12
-13813.48
41.62
ROE (%) -103.17
KERX's ROE (%) is ranked lower than
82% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. KERX: -103.17 )
Ranked among companies with meaningful ROE (%) only.
KERX' s ROE (%) Range Over the Past 10 Years
Min: -246.34  Med: -105.33 Max: 68.51
Current: -103.17
-246.34
68.51
ROA (%) -81.79
KERX's ROA (%) is ranked lower than
83% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. KERX: -81.79 )
Ranked among companies with meaningful ROA (%) only.
KERX' s ROA (%) Range Over the Past 10 Years
Min: -135.67  Med: -73.82 Max: 31.09
Current: -81.79
-135.67
31.09
ROC (Joel Greenblatt) (%) -1734.22
KERX's ROC (Joel Greenblatt) (%) is ranked lower than
68% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. KERX: -1734.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KERX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -46369.35  Med: -8455.68 Max: 7114.49
Current: -1734.22
-46369.35
7114.49
Revenue Growth (3Y)(%) 19.70
KERX's Revenue Growth (3Y)(%) is ranked higher than
78% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. KERX: 19.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KERX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -50.00 Max: 268.4
Current: 19.7
0
268.4
EBITDA Growth (3Y)(%) 41.60
KERX's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. KERX: 41.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KERX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.1  Med: 16.55 Max: 71.3
Current: 41.6
-45.1
71.3
EPS Growth (3Y)(%) 42.80
KERX's EPS Growth (3Y)(%) is ranked higher than
90% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. KERX: 42.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KERX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.7  Med: 15.75 Max: 60.5
Current: 42.8
-44.7
60.5
» KERX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

KERX Guru Trades in Q4 2014

Seth Klarman 18,300,000 sh (unchged)
» More
Q1 2015

KERX Guru Trades in Q1 2015

Seth Klarman 22,380,200 sh (+22.30%)
» More
Q2 2015

KERX Guru Trades in Q2 2015

Jim Simons 295,500 sh (New)
Seth Klarman 25,791,678 sh (+15.24%)
» More
Q3 2015

KERX Guru Trades in Q3 2015

Paul Tudor Jones 14,068 sh (New)
David Abrams 5,000,000 sh (New)
Seth Klarman 25,791,678 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 4.06
KERX's Forward P/E is ranked higher than
92% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 16.75 vs. KERX: 4.06 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.78
KERX's P/B is ranked lower than
57% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. KERX: 2.78 )
Ranked among companies with meaningful P/B only.
KERX' s P/B Range Over the Past 10 Years
Min: 1.88  Med: 6.75 Max: 49
Current: 2.78
1.88
49
P/S 38.03
KERX's P/S is ranked lower than
82% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. KERX: 38.03 )
Ranked among companies with meaningful P/S only.
KERX' s P/S Range Over the Past 10 Years
Min: 1.1  Med: 82.75 Max: 1911
Current: 38.03
1.1
1911
Current Ratio 4.83
KERX's Current Ratio is ranked higher than
52% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. KERX: 4.83 )
Ranked among companies with meaningful Current Ratio only.
KERX' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 7.47 Max: 106.93
Current: 4.83
1.88
106.93
Quick Ratio 3.63
KERX's Quick Ratio is ranked lower than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. KERX: 3.63 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 7.47 Max: 106.93
Current: 3.63
1.88
106.93
Days Inventory 1.00
KERX's Days Inventory is ranked higher than
99% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. KERX: 1.00 )
Ranked among companies with meaningful Days Inventory only.
KERX' s Days Inventory Range Over the Past 10 Years
Min: 2886.82  Med: 2886.82 Max: 2886.82
Current: 1
Days Sales Outstanding 113.30
KERX's Days Sales Outstanding is ranked lower than
76% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. KERX: 113.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.51  Med: 28.12 Max: 2248.5
Current: 113.3
0.51
2248.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.09
KERX's Price/Net Cash is ranked higher than
73% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 18.00 vs. KERX: 5.09 )
Ranked among companies with meaningful Price/Net Cash only.
KERX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.09  Med: 7.31 Max: 29.11
Current: 5.09
1.09
29.11
Price/Net Current Asset Value 3.06
KERX's Price/Net Current Asset Value is ranked higher than
78% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. KERX: 3.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KERX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 7.20 Max: 26.2
Current: 3.06
1.07
26.2
Price/Tangible Book 2.96
KERX's Price/Tangible Book is ranked higher than
72% of the 1051 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. KERX: 2.96 )
Ranked among companies with meaningful Price/Tangible Book only.
KERX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.93  Med: 6.23 Max: 26.2
Current: 2.96
0.93
26.2
Price/Median PS Value 0.50
KERX's Price/Median PS Value is ranked higher than
77% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. KERX: 0.50 )
Ranked among companies with meaningful Price/Median PS Value only.
KERX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 1.42 Max: 23.02
Current: 0.5
0.02
23.02
Earnings Yield (Greenblatt) (%) -53.39
KERX's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. KERX: -53.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KERX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -50.85  Med: 176.85 Max: 27616.5
Current: -53.39
-50.85
27616.5

More Statistics

Revenue(Mil) $8
EPS $ -1.27
Beta3.17
Short Percentage of Float30.02%
52-Week Range $2.80 - 14.89
Shares Outstanding(Mil)105.19

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 22 80 207 390
EPS($) -0.98 -0.34 0.82 2.01
EPS without NRI($) -0.98 -0.34 0.82 2.01

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:KYX.Germany,
Keryx Biopharmaceuticals Inc was incorporated in Delaware in October 1998. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. It is developing ZerenexTM an oral, ferric iron-based compound. It has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease, or CKD, on dialysis, conducted pursuant to a Special Protocol Assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA. Its New Drug Application, or NDA, is currently under review by the FDA with an assigned Prescription Drug User Fee Act, or PDUFA. It has also completed a U.S.-based Phase 2 study of Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 NDD-CKD. Currently, its only drug candidate is Zerenex. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.
» More Articles for NAS:KERX

Headlines

Articles On GuruFocus.com
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016 
Seth Klarman Blames Market, Investments for Rare Down Year Jan 25 2016 
David Abrams Buys Stake in Heavy Equipment Company Dec 15 2015 
Why Seth Klarman Keeps Buying Keryx Biopharma Nov 03 2015 
Seth Klarman Raises Position in Keryx Biopharmaceuticals Oct 21 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Is Seth Klarman right about Keryx Inc.? Jun 25 2015 
Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics Inc, May 15 2015 
Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data May 05 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 

More From Other Websites
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016
Keryx Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:KERX) : January 4, 2016 Jan 04 2016
Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 31,... Dec 31 2015
Keryx Biopharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday,... Dec 22 2015
Keryx Biopharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday,... Dec 22 2015
XBI Recovers from Its Slump Dec 21 2015
Technical Briefing on Biotechnology Equities -- Keryx Biopharma, Cytokinetics, Curis, and BioTime Dec 17 2015
Equities Lead Investor Sentiment - Research Reports on TriNet Group, Xencor, Keryx... Dec 11 2015
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Dec 10 2015
Keryx Announces Appointment of John P. Butler to its Board of Directors Dec 10 2015
Keryx Announces Appointment of John P. Butler to its Board of Directors Dec 10 2015
KERYX BIOPHARMACEUTICALS INC Financials Dec 08 2015
Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 8,... Dec 08 2015
Hedge Funds Are Selling Keryx Biopharmaceuticals (KERX) Dec 05 2015
Keryx Biopharmaceuticals Announces Webcast of Presentation at Oppenheimer's 26th Annual Healthcare... Dec 01 2015
Keryx Biopharmaceuticals Announces Participation at Two Upcoming Investor Conferences Nov 03 2015
XBI Fell the Most as the Small-Caps Took a Hit Oct 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK